Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Johnson & Johnson Gains Rights to Yuhan’s Experimental Lung Cancer Drug Lazertinib

By Catherine Sbeglia | November 7, 2018

In a licensing deal potentially worth more than $1.2 billion, Janssen, Johnson & Johnson’s Biotech unit, has gained global rights—excluding South Korea—to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) Lazertinib for the treatment of patients with non-small cell lung cancer (NSCLC).

Janssen will make an upfront payment of $50 million for Lazertinib. Yuhan’s also will be eligible for approximately $1.2 billion in developmental and commercialization milestones, as well as double-digit royalties on sales, if the experimental drug is approved.  

In return, Janssen will assume responsibility for development, manufacturing, and commercialization with exclusive worldwide rights to Lazertinib excluding Korea, where Yuhan is currently conducting studies of Lazertinib. 

Interim results of current phase 1 and 2 clinical trials show Lazertinib exhibits promising systemic and intracranial antitumor activities at multiple dose levels and was well-tolerated with low rates of Grade 3 or higher adverse events.

Yuhan believes that these results suggest that Lazertinib, a potent, mutant-selective, irreversible, brain-penetrant, and orally active inhibitor NSCLC shows the potential to become a first-line therapy. The company says the drug may offer the possibility of a wider therapeutic index, making it a potential best-in-class candidate as a combination regimen. 

If successful development and approval are achieved, Lazertinib is expected to become serious competition for AstraZeneca’s Tagrisso (osimertinib), which was approved by the FDA in April as a first-line therapy for NSCLC patients with EGFR mutations.

(Sources: Korea Herald; Pulse News)

Related Articles Read More >

Endevica
Investigational drug promises to reverse wasting syndrome in cancer patients
Nodular melanoma
BioNTech and Moderna set their sights on treating cancer
4D Path
4D Path and University of Leeds extend partnership to validate oncology platform
Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards